Biblio Discovery — Demo Discovery Service

4 hasil untuk "Yawei Liu"

Menampilkan 1–4 · 1,56 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials

    Yongchuan Li; Yawei Liu; Lili Fu dkk.

    PLoS ONE, Vol. 7 No. 4 · 2012 · Inggris · PLOS Scopus

    Background: A few studies focused on statin therapy as specific prophylactic measures of contrast-induced nephropathy have been published with conflicting results. In this meta-analysis of randomized controlled trials, we aimed to assess the effectiveness of shor-term high-dose statin treatment for…

  2. Artikel Jurnal Teks lengkap

    Resurgent threat in a changing climate: A 20-year bibliometric analysis of global Chikungunya research evolution and pandemic preparedness

    Xiaoyi Xu; Liming Ye; Yawei Liu dkk.

    PLOS Neglected Tropical Diseases, Vol. 20 No. 2 · 2026 · Inggris · PLOS Scopus

    Background: Driven by climate change and urbanization, chikungunya virus (CHIKV) has evolved from being a localized pathogen to being a global pandemic threat. This bibliometric analysis maps 20 years (2004–2025) of global CHIKV research to identify priorities and gaps in pandemic preparedness…

  3. Artikel Jurnal Teks lengkap

    Rosiglitazone Inhibits Transforming Growth Factor-β1 Mediated Fibrogenesis in ADPKD Cyst-Lining Epithelial Cells

    Yawei Liu; Bing Dai; Chenggang Xu dkk.

    PLoS ONE, Vol. 6 No. 12 · 2011 · Inggris · PLOS Scopus

    Background: Interstitial fibrosis plays an important role in progressive renal dysfunction in autosomal dominant polycystic kidney disease (ADPKD). In our previous studies, we confirmed that PPAR-γ agonist, rosiglitazone could protect renal function and prolong the survival of a slowly progressive…

  4. Artikel Jurnal Teks lengkap

    Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib

    Qiang Huang; Changhua Zhou; Xiao Chen dkk.

    PLOS ONE, Vol. 10 No. 10 · 2015 · Inggris · PLOS Scopus

    Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To improve the therapeutic index of Sunitinib, a prodrug strategy was employed to modify Sunitinib…